Abstract | Improvements in protocol-driven clinical trials and supportive care for children and adolescents with cancer have reduced mortality rates by more than 50% over the past three decades. Overall, the 5-year survival rate for patients with pediatric cancer has increased to approximately 80%. Recognition of the biological heterogeneity within specific subtypes of cancer, the discovery of genetic lesions that drive malignant transformation and cancer progression, and improved understanding of the basis of drug resistance will undoubtedly catalyze further advances in risk-directed treatments and the development of targeted therapies, boosting the cure rates further. Emerging new treatments include novel formulations of existing chemotherapeutic agents, monoclonal antibodies against cancer-associated antigens, and molecular therapies that target genetic lesions and their associated signaling pathways. Recent findings that link pharmacogenomic variations with drug exposure, adverse effects, and efficacy should accelerate efforts to develop personalized therapy for individual patients. Finally, palliative care should be included as an essential part of cancer management to prevent and relieve the suffering and to improve the quality of life of patients and their families.
Introduction
Major advances have been made in understanding the pathogenesis and treatment of pediatric cancers since the introduction of modern therapies half a century ago.
The growing ability to analyze the genetic and epigenetic abnormalities in tumor cells is driving the discovery of somatic mutations and their role in oncogenesis. Mutations in more than 1.6% of the approximately 22,000 coding human genes have been implicated in carcinogenesis and, to date, the number of known cancer genes has grown to 457, many of which are involved in childhood cancer. 1 The next generation of highly parallel, single-molecule DNAsequencing platforms will hopefully identify many more genetic alterations in tumor cells. 2 In parallel to these biological advances, there has been a remarkable improvement in the survival rates for pediatric patients with cancer. Among children 0-19 years old, the 5-year relative survival rate for all cancer combined has increased from 61.7% in 1975-1977 to 81.4% in 1999-2006 , as estimated by the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute. 3 With the exception of gliomas, the 5-year relative survival rate has now exceeded 55% for all major types of childhood cancer (Table 1 ). This advance can be attributed to the enrollment of large numbers of patients in well-designed prospective clinical trials, improved risk assessment and supportive care, and the development of drugs directed at specific targets, which has partly been achieved through the use of preclinical models. Between 1975 and 2007, the mortal ity rates for all childhood cancers combined decreased by more than 50%. This decrease was led by a 75% reduction in the mortality rate (from 0.4 to 0.1 per 100,000) of non-Hodgkin lymphoma (NHL) and a 60% reduction (from 1.0 to 0.4 per 100,000) of acute lympho blastic leukemia (ALL) and acute myeloid leukemia (AML). 3 As a result, NHL and ALL are now among the most curable childhood cancers ( Figure 1 ). By contrast, the survival rates for children with other solid tumors, Of note, there is marked heterogeneity within each type of pediatric cancer, such that the survival rate varies substantially according to the disease stage, acquired genetic abnormalities, and age at clinical presentation ( Figure 2 ). The current challenge is to improve not only the cure rates for high-risk (difficult-to-treat) subtypes of childhood cancer, but also the overall quality of life of patients. In this Review, we describe the newly discovered genetic subtypes of cancers, the development of targeted therapies against molecular lesions, and major issues facing pediatric oncologists. We focus on the subtypes for which substantial advances in the understanding of biology and treatment have been made.
Acute lymphoblastic leukemia
As the 5-year survival rates in childhood ALL improved to more than 84%, 3, 4 many conventional factors that have guided prognosis-such as gender and race-are no longer useful. Historically, compared with younger children, adoles cents had a much worse treatment outcome due to an increased prevalence of high-risk leukemia and poorer tolerance and adherence to therapy. Now, adolescents have similar high cure rates to those of younger children owing to the use of risk-adjusted intensive chemo therapy including glucocorticoids, vincristine, asparaginase and triple intrathecal therapy, provided compliance is closely monitored. 5, 6 Philadelphia chromosome-positive ALL-resulting in the gene fusion BCR-ABL1 and once associated with a dismal prognosis-is no longer considered to be an absolute indication for allogeneic transplantation during first remission. In 2009, the Children's Oncology Group (COG) reported a 3-year event-free survival (EFS) of 80% (CI 64-90%) in patients treated with continuous imatinib-a tyrosine kinase inhibitor (TKI)-and intensive chemo therapy, compared with approximately 35% for historical controls. 7 Although the impact of this treatment on long-term EFS is unknown, many investi gators reserve allo geneic transplantation for therapy after relapse in children with Philadelphia chromosome-positive ALL. Ongoing studies-such as AALL0622-will determine whether new and more potent TKIs 8 (such as dasatinib) will further improve outcome. Moreover, these studies will help to determine if chemo therapy intensity can be reduced in patients with favorable early responses. To this end, two studies showed that with effective intra thecal and systemic therapy, 9 prophylactic cranial irradiation (once a standard treatment) can be safely omitted in all patients, regardless of their presenting features. 10, 11 These studies yielded excellent 5-year EFS rates of 85.6% and 81%, and low rates of isolated central nervous system (CNS) relapse (2.7% and 2.6%), respectively. 10, 11 In the first study, only one of 498 patients developed a secondary myelodysplastic syndrome. 10 Key points ■ Prophylactic cranial irradiation can be omitted from the treatment of patients with acute lymphoblastic or myeloid leukemia, with the use of effective systemic and intrathecal therapy ■ Vigilant supportive care can reduce morbidity and mortality, and improve eventfree survival of acute myeloid leukemia ■ The next generation of treatment for brain tumors will be tailored to specific molecular subtypes of disease to improve the cure rates and reduce the long-term sequela of therapy ■ The cure rates have improved dramatically over the past three decades for patients with localized solid tumors and hematologic cancers ■ Patients with disseminated disease continue to fare poorly and some are now receiving targeted therapies against specific molecular alterations ■ Integration of palliative care into the ongoing care of children with cancer improves the quality of pediatric oncology care
Several high-risk subtypes of ALL still pose thera peutic challenges (Table 2) . Early T-cell precursor ALL-a subset of T-cell ALL characterized by immature genetic and immunophenotypic features-does not respond well to conventional therapy, such as pred nisone, vincristine and asparaginase. 12 Treatments under investigation for this subtype of ALL include nelarabine, 8 allogeneic transplantation, 4 and high-dose dexamethasone (10 mg/m 2 per day). 13 In patients with T-cell ALL with a good response to upfront prednisone, treatment with highdose dexa methasone during remission induction yielded a cumulative relapse of approximately 6% compared with a relapse rate of approxi mately 20% in patients treated with prednisone during remission induction. 13 Despite intensive chemotherapy and allogeneic transplantation, infants with some subtypes of ALL (including MLL generearrangements) continue to have a dismal prognosis due to relapse. [14] [15] [16] Potential therapeutics for these infants include an inhibitor against FLT-3 (lestaurtinib), which has schedule-dependent synergistic effects with chemotherapy for MLL-rearranged leukemia in preclinical studies, 17 and DNA methyltransferase inhibitors, as aberrant DNA methylation occurs in the majority of these cases.
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IKZF1 (encoding the lymphoid transcription factor Ikaros) is deleted in 80% of cases of BCR-ABL1 positive ALL. 19 Large-scale genome-wide analyses have identified a high-risk subgroup of BCR-ABL1 negative B-cell precursor ALL that is also characterized by IKZF1 deletion, 20, 21 and another high-risk subtype of B-cell precursor ALL with overexpression of CRLF2 (encoding for cytokine receptor-like factor 2 [CRLF-2]). 22, 23 Mullighan et al. 20 described cumulative rates of relapse of 47.0% and 24.6% at 10 years in the original cohort of patients, and 73.8% and 25.0% at 5 years in the validated cohort with or without IKZF1 deletion, respectively. High levels of expression of CRLF-2 were associated with a significantly (P = 0.006) higher 6-year cumulative risk of relapse (31% versus 11% in patients with low expression). 23 The presence of activating mutations in the JAK family of protein kinases in both of these subtypes 4 offers the possibility of treating these patients with JAK inhibitors. Identification of new mutations affecting transcriptional and epigenetic regulation as a mechanism of drug resistance raises the possibility of reversing the aberrant epigenetic alterations using drugs such as histone deacetylase inhibitors, but no clinical data are available yet. 24 Hypodiploidy, translocation t(17;19)(q22;p13.3) TCF3-HLF, and poor responses to early treatment (such as induction failure and a high level [≥1%] of minimal residual disease [MRD] at the end of remission induction) are features associated with poor prognosis, despite the use of allogeneic transplantation. 25 Promising novel thera peutics under investigation include natural killer (NK) cell transplantation using donor NK cells that express inhibitory killer-cell immunoglobulin receptors in the absence of ligand in the recipient-that is, receptor-ligand mismatch-and immunotherapy with conjugated antibodies, bispecific T-cell-engager singlechain antibodies (such as blinatumomab), and chimeric T-cell receptors. 4, 26 Intensive use of glucocorticoids, asparaginase and methotrexate in contemporary clinical trials has led to an increased prevalence of osteonecrosis, especially in adolescents aged 10-20 years, partly because of slower systemic clearance of glucocorticoids in this group. 27 Studies are under way to determine whether early detection of this complication by prospective MRI 27 or interrupted use of glucocorticoids-CCG 1961 trial-would decrease the severity of this complication.
Acute myeloid leukemia
As in ALL, identification of specific genetic abnormalities and early treatment response represent ways to assess the risk of induction failure or relapse in current clinical protocols for AML. Subtypes of AML with t(8;21) ETO-AML1, inv(16) MYH11-CBFB, t(15;17) PML-RARα, or mutations of CEBPA (encoding for CCAAT/ enhancer-binding protein alpha) or NPM (encoding for nucleophosmin) are highly curable without the use of allogeneic transplantation. 4, 28 By contrast, monosomy 7, abnormalities in 5q, t(6;9)(p23;q34), and internal tandem duplications of FLT3-particularly when associated with a high mutant to wild-type allelic ratio-are associated with 5-year EFS below 40% despite the use of allogeneic transplantation. 4, [28] [29] [30] Several clinical trials are testing various FLT-3 inhibitors with or without transplantation in 10-15% of patients with internal tandem duplications of FLT3. Acute megakaryoblastic leukemias-with the exception of the 2-3% of those with t(1;22) RBM15-MKL1-continue to confer a poor prognosis. 28 Response to induction therapy, as assessed by MRD assays, is one of the most reliable prognostic indicators 
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Hodgkin lymphoma of AML. 4, 28 In the AML02 study, patients with low levels of MRD (0.1% to <1%) after the first course of remission induction had a similar favorable response to those with undetectable MRD. 28 These results suggested that this treatment strategy has abrogated the adverse prognosis previously associated with a poor early treatment response. However, patients with MRD above 1% have an estimated 3-year EFS of only 32%, despite allogeneic transplantation. 28 Thus, novel therapies are needed for this patient subgroup. One promising approach is the use of NK-cell transplantation, which yielded a 2-year EFS of 100% (95% CI 63.1-100%) in 10 patients treated after completion of chemotherapy in first complete remission. 31 A major component of AML treatment is the use of an anthracycline; however, intensive use is associated with cardiomyopathy. 32 Attempts to reduce the debilitating late effect of anthracyclines include dose reduction or replacing some of the doses with other drugs such as cladribine, fludarabine, and clofarabine. 33 Although many studies have shown that allogeneic transplantation improves the overall relapse-free survival rate in AML, there is no consensus on the indications for this treatment modality or on the most suitable donors or optimal preparative regimens. Less controversial is the omission of cranial irradiation in AML, a strategy that proved successful in the AML02 study, which resulted in an overall 3-year EFS of 63.0% and 3-year survival of 71.1%. 28 Infectious complications remain a major cause of morbidity and mortality for patients with AML. Prophylactic treatment with cefepime or vancomycin plus ciprofloxacin during periods of leukopenia, significantly reduced bac terial infection, febrile neutropenia and the duration of hospitalization without increasing fungal infection. 34 Although controlled trials are still needed to firmly establish its efficacy, antifungal prophylaxis has been widely adopted. Among the available antifungal treatments, fluconazole and itraconazole are not recommended-not only because they inhibit cytochrome P450 enzymes, thereby affecting chemotherapy efficacy or toxicity, but also because they are not effective against Aspergillus species. 35 Finally, prophylactic granulo cyte colony-stimulating factor (G-CSF) is not recommended in AML because it does not reduce morbidity or mortality and is associated with an increased risk of relapse in cases that overexpress differentiation-defective G-CSF receptor isoform IV. 36 Central nervous system tumors Medulloblastoma Cure rates for patients with newly diagnosed medulloblastoma-the most common malignant CNS tumor in childhood-have steadily improved over the past three decades. Current forms of multimodality therapy can cure more than 80% of patients with standard-risk disease and more than 60% with high-risk presentations, 37 compared with 40% of the patients treated three decades ago. 38 Gene-expression profiling studies have demonstrated that medulloblastoma actually encompasses four or five molecular diseases with distinct clinical, pathological and prognostic features. [39] [40] [41] The subgroup of adolescents with mutations in the components of the Wnt and β-catenin signaling pathway constitute about 15% of patients with an excellent prognosis and a 5-year EFS rate of more than 95% with conventional therapy. 39 The subgroup of patients with mutations in components of the hedgehog signaling pathway (HH)-which comprise about 20-25% of the patients with medulloblastoma and who have mutations in PTCH, SMO and SUFU-have an intermediate prognosis with 5-year EFS rate of 75-85% when treated with conventional therapy. 41 Introduction of targeted therapy directed to the HH pathway promises to improve the outcome for these patients by potentially reducing the need for cytotoxic chemotherapy. 42 The remaining 60-65% of patients-including a small proportion of patients with MYC amplification-have an inferior prognosis (~60% 5-year EFS) when treated with conventional therapy. 41 Current research efforts are focused on developing targeted agents that block signaling pathways associated with each molecular subtype of the disease. 
Ependymoma
The extent of surgical resection, histological grade and the presence of metastatic disease are key prog nostic factors for ependymomas-tumors that arise from ependymal cells that line the ventricles in the CNS. 43 A prospective study demonstrated that approximately 69% of patients with ependymoma can be cured at 7 years of follow up when treated with aggressive surgical resection and local conformal radiation therapy. 44 Gain of chromosome 1q25 and homozygous deletion of CDKN2A (encoding for the tumor suppressor p16-INK4α) negatively impact the survival of these patients with 5-year overall survival of 30-82% and 10-76%, respectively, whereas gain of chromo somes 9q34, 15q22, 18q21 and loss of 6q23 are associated with excellent survival. 45 A more-extensive genomic analysis with single nucleotide polymorphism data has classified ependymoma into nine molecular subtypes based on tumor location and chromosomal changes. 46 On this basis, several candidate genes (for example, THAP11, PSPH, EPHB2, KCNN1, RAB3A, NOTCH1, PTEN and CDKN2A) have emerged that may have a role in ependymoma pathogenesis. 46 Novel therapeutic approaches targeting signaling pathways crucial to the malignant transformation of neural stem cells, such as Notch inhibitors, are being tested in clinical trials. 47, 48 No data are currently documented on approaches for patients with gain of 1q25 or loss of CDKN2A.
High-grade and diffuse-pontine glioma Despite aggressive surgical resection, high-dose radiation therapy, chemotherapy, and autologous bone-marrow transplantation, the outcome of patients diagnosed with high-grade glioma and diffuse-pontine glioma remains dismal. 49 Chemotherapeutic agents that demonstrated some efficacy in adult gliomas (for example, temozolomide, irinotecan and bevacizumab) have showed disappointing results in pediatric gliomas. 50, 51 Genomic analysis of adult high-grade glioma offers insight into the molecular pathogenesis of the adult disease. 52, 53 Abnormalities in specific genes-such as IDH1 (encoding for isocitrate dehydrogenase 1), PDGFRA (encoding for platelet derived growth factor A), EGFR, NF1 (encoding for neuro fibromin 1), RB, TP53-and signaling pathways (for example RTK/RAS/PI3K) have been implicated in malignant trans formation. 53 Similar analyses of pediatric tumors have demonstrated key differences between adult and pediatric high-grade glioma. These include the absence of hot-spot mutations in IDH1 and the presence in pediatric tumors of focal amplification of PDGFRA that are absent in adults, and explain some of the different responses to chemotherapy. 54, 55 Despite efforts to devise novel translational approaches to therapy, effective treatment remains elusive and presents a major challenge to the field.
Low-grade gliomas
Low-grade gliomas that are localized in areas amenable to gross total resection can be cured by surgery alone with minimal morbidity. 56 Tumors located in the midline (chiasmatic-hypothalamic) are often not surgically resectable, leading to significant morbidity-such as visual impairment or blindness and endocrine abnormalities. Chemotherapy and irradiation remain effective against low-grade glial tumors, but are often not curative. 57 The major molecular alterations in low-grade gliomas include duplication, activating mutations and fusion transcripts (KIAA1549-BRAF), implicating the MAPK pathway in 88 
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Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; FGFR, fibroblast growth factor receptor; GSK-3, glycogen synthase kinase 3 IGF-1R, insulin-like growth factor receptor; mTOR, mammalian target of rapamycin; PARP, poly (ADP) ribose polymerase; PDGFR, platelet-derived growth factor receptor.
the pathogenesis of these tumors. [58] [59] [60] [61] In addition to advanced radiation therapy techniques, finding effective agents with minimal associated morbidity that target the MAPK pathway in the CNS should be a research priority for curing low-grade gliomas.
Infant brain tumors
The vulnerability of the infant brain to the adverse effects of surgery, chemotherapy and irradiation underscores the fundamental problem hindering the development of curative treatment approaches for this patient group. Desmoplastic medulloblastoma in infancy has a high cure rate with surgery and chemotherapy alone. 62 Most of these tumors have mutations in the HH pathway and may be cured with targeted therapies in the future. 39 Compared with older children, infants with high-grade gliomas and brain-stem tumors have an overall survival of 60%, suggesting that these tumors are molecularly different from the same tumors in older patients. 63 Atypical teratoid rhabdoid tumors (ATRT) constitute a rare, but important, subgroup of infant brain tumors with a very poor prognosis (overall survival <20%). 64 The molecular hallmark signature of ATRT is deletion of SMARCB1 (encoding the chromatin regulator BAF47), detected by presence of monosomy 22 and the absence of BAF47 staining on immunohistochemistry. 65 A small subgroup of these patients presents with synchronous renal and ATRT. 66 Current therapy for infant brain tumors focuses on tailoring the intensity of therapy to predicted outcome, hence reducing the risk of long-term toxic effects in the survivors. Genomic analysis of tumors from this patient group will further inform us of key differences in their pathogenesis as compared with their older counterparts.
Neuroblastoma
Neuroblastoma, the most common extracranial solid tumor in childhood, is readily cured in about 70% of patients. 67 Baker et al. 68 reported overall 5-year survival rates in excess of 95% in children with intermediaterisk disease treated with reduced-intensity risk-based chemo therapy. By contrast, among patients with highrisk disease-defined by segmental chromosomal aberrations such as amplification of MYCN-the cure rate is much lower with induction chemotherapy, myeloblative consolidation therapy, and maintenance therapy with isotretinoin. 67 The addition of the anti-GD2 antibody, ch14.18, with alternating cycles of interleukin-2 or granulocyte macrophage-CSF (GM-CSF) in addition to isotretinoin, has been reported to improve the 2-year EFS of these patients to 66%, a 20% increase over the 2-year EFS of patients who received isotretinoin alone. 69 Promising results in the relapse setting suggested that radiolabeled I 131 -metaiodobenzylguanidine or I 123 -metaiodobenzylguanidine should also be explored as consolidation therapy in high-risk patients. 67 Moreover, the discovery of ALK mutations or amplifications in about 15% of newly diagnosed neuroblastoma cases has prompted the development of treatment to inhibit this target. 70 Finally, the Pediatric Preclinical Testing Program has identified an aurora kinase A inhibitor (MLN8237) and the replication-competent RNA virus Seneca Valley virus as potential active agents. 71, 72 Rhabdomyosarcoma Around 75% of children and adolescents with localized rhabdomyosarcoma survive. However, patients with metastatic disease and at least two adverse presenting factors (such as age 12 months or younger or 10 years or older, bone marrow involvement, and three or more metastatic sites) fare poorly, with a 3-year EFS of less than 20%. 73 Indeed, an analysis of 542 children and adolescents with high-risk rhabdomyosarcoma enrolled in Intergroup  Rhabdomyosarcoma Studies (IRS III, The current challenge is to develop effective treatments that reduce or eliminate the use of radiation or alkylating agents for low-risk cases and incorporate novel therapies for high-risk cases. In cell lines and animal model systems, insulin-like growth factor 1 receptor (IGF-1R) has important roles in the proliferation, stress response and survival of rhabdomyosarcoma cells, via the AKT protein. 74 Thus, the COG is currently evaluating the feasibility of adding the IGF-1R monoclonal antibody, IMC-A12, to standard chemotherapy in patients aged 10 years or older with metastatic embryonal rhabdomyosarcoma and in all patients with metastatic alveolar rhabdomyosarcoma (trial ARST08P1). In rhabdomyosarcoma xenograft models, the anti-IGF-1R antibody h7C10 synergized with rapamycin causing a reduction in tumor growth and phosphorylated AKT levels. 74 Future trials should also explore this treatment combination. HH pathway activation has been documented in subgroups of patients with rhabdo myosarcoma and targeting this pathway may benefit patients with embryonal and fusion gene-negative tumors. 75 Aberrant MET signaling has been identified in mouse models and gene-expression studies of rhabdomyosarcoma, suggesting that the inhibition of this pathway may also be useful in the treatment of the disease. 76 Moreover, mutations in FGFR4 were found in 7% of primary rhabdomyosarcomas, providing a rationale for targeting this gene. 77 Other potential targets include MYCN, the chemokine (C-X-C motif) receptor 4-stromal cell-derived factor 1 (CXCR-4-SDF-1) axis, PDGFR, cyclins D2 and D3, VEGF, and GSK-3. 78, 79 Finally, in a study of 120 rhabdomyosarcoma specimens, gene-expression analysis identified a 34-probe set model that was highly predictive of clinical outcome and correlated well with the current risk stratification system used by the COG. 80 This strategy may help improve risk-adapted therapies and identify additional targets for therapy.
Other soft-tissue sarcomas
Non-rhabdomyosarcoma soft-tissue sarcomas are a heterogeneous group of tumors that account for about 4% of all pediatric cancers. 3 These tumors are relatively chemoresistant, more commonly affect adults, and have been under studied in the pediatric population. Effective treatment of adults with soft-tissue sarcoma has been achieved by the use of targeted therapies, including imatinib for KIT-mutated gastrointestinal stromal tumor (GIST) 81 and crizotinib for ALK-rearranged inflammatory myofibroblastic tumor. 82 However, the histologic distribution and biology of some of these entities-including GIST and infantile fibrosarcoma-differ between childhood and adult cases. 83, 84 For example, activating mutations in KIT or PDGFRA are found in >90% of adult GISTs, but in only 11% of childhood cases; 85 thus, targeted therapies commonly used in adults-such as imatinib -are expected to be less effective in pediatric patients. By contrast, IGF-1R and the mitochondrial succinate dehydrogenase complex (SDHB) seem to be pivotal in the pathogenesis of pediatric and wild-type GISTs, 85, 86 suggesting that these pathways should be preferentially exploited in childhood cases.
Ewing sarcoma family of tumors
The Ewing sarcoma family of tumors-a group of bone and soft-tissue tumors derived from mesenchymal progenitor cells characterized by rearrangements of the EWS gene-includes classic Ewing sarcoma, Askin tumor, and peripheral primitive neuroectodermal tumor. Although several different regimens are available for treating these tumors, they all use similar drugs (vincristine, doxorubicin, cyclophosphamide, ifosfamide and etoposide) and local control measures such as radiation therapy, surgery or both. To date, 70-80% of the patients who present with localized disease are cured but only about 25% of those with meta stases survive, many of whom suffer from short-term and long-term treatment-related toxic effects. 87 The EWS-ETS family of fusion genes, their transcripts and protein products, and the pathways they activate all provide promising targets for therapy. The most attractive candidate agents are IGF-1R inhibitors, which have produced responses as single agents in about 10% of patients with relapsed disease. 88 Other potential agents include inhibitors of PDGFR, mTOR (in combination with IGF-1R inhibitors), SRC, VEGF, and CD99, as well as the Seneca Valley virus and the kinesin spindle protein inhibitor ispinesib. 72, 89 Osteosarcoma Approximately 70% of patients with localized osteosarcoma are cured with current treatment but less than 30% of those patients with metastatic disease survive. 90 The search for specific genetic alterations in osteosarcoma -the most common primary bone tumor in children and adolescents-has yet to uncover any consistent lesions that could be used to develop targeted therapy. Instead, tumors are characterized by a complex karyotype, aneuploidy, and dysregulation of numerous pathways and genes including RB, TP53, CDKN2A, RECQL4, MET, FOS, mTOR, WNT, NOTCH, IGF1, EGFR, VEGFR, PDGFR, MYC, HER2, and Ezrin. 91 This characterization has complicated efforts to devise effective targeted therapies. Promising new therapeutic approaches include administration of the immunostimulant muramyl tripeptide phosphatidylethanolamine, the combination of IGF-1R and mTOR inhibitors, SRC kinase inhibition, immune targeting of HER2, angiogenesis inhibition (inhibition of VEGF), and agents that target the MET, receptor activator of nuclear factor κB ligand (RANKL), and Notch pathways.
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Retinoblastoma
Most children with retinoblastoma can be cured with enucleation and radiation, whereas patients with metastatic disease require systemic treatment. 94 The current 5-year survival rate for all patients with retinoblastoma is 96.5%, compared with 92.3% 30 years ago. 95 Therapeutic objectives in retinoblastoma include not only improved survival but also eye salvage with good vision and cosmesis. 96 Advanced intraocular retinoblastoma poses a particular therapeutic challenge as current intensified therapy, especially radiation, increases the risk of second ary malignancies. 97 Treatments under investigation include chemotherapeutic agents such as topotecan, 98 and different methods of local drug delivery, such as sub conjunctival, 98 intra-arterial, 99 intravitreal, 100 and episcleral implants for sustained release. 101 The discovery of inactivation of p53 via MDMX amplification in promoting human retino blastoma suggests that MDMX inhibitors, such as nutlin-3, might be effective for the treatment of this disease. 102 
Rare cancers
Rare cancers account for 9% of childhood cancers and offer a unique opportunity to study novel mechanisms of disease. For example, adrenocortical carcinoma is a rare malignancy in childhood and adolescence. However, a high incidence of this disease has been observed in children in southern Brazil, a finding that has led to the discovery of unique germline TP53 mutations that contribute to its pathogenesis. 103 Most children with adreno cortical tumors-particularly those under 4 years of age-have inherited mutations in TP53. Similarly, pleuro pulmonary blastoma is a very rare malignant embryonal mesenchymal tumor of the lung and pleura that arises during fetal lung development; up to 40% of the patients may have genetic predisposition to this cancer. A family-based linkage study found that DICER1-a gene encoding ribonuclease III endo nuclease that participates in the processing of small RNAs-was mutated in this type of tumor. 104 
Palliative care
The most prevalent symptoms pediatric patients experience are pain, fatigue, nausea or vomiting, constipation and weight loss; however, the type and severity of symptoms vary by disease and their prevalence is highest for patients with solid tumors, patients who are hospitalized, undergo stem-cell transplantation, receive chemo therapy, or receive palliative care at the end of life. 105, 106 Parents of children with cancer report poorer quality of life compared with population norms; 107 many parents experience distress from having to make difficult end-of-life care decisions, such as participating in phase I clinical trials, withholding or withdrawing life-sustaining treatments, foregoing cancer chemotherapy, talking to their children about death, or deciding on the location of their last days. 108, 109 Bereaved parents are at increased risk of experiencing anxiety and depression for many years after their child's death. 110 Most parents of children with advancedstage cancer desire both cancer-directed therapy and comfort-directed care. 111 They also value effective communication and interpersonal relationships as important components of high-quality end-of-life care, and prefer to experience the death of their child at home. 112, 113 Palliative care that addresses the multiple physical, emotional, social, and spiritual issues should be provided concomitantly with cancer-directed treatment to improve the quality of care. 114, 115 Integration of palliative care into the ongoing care of children with cancer may be achieved by facilitating access to hospice and palliative care services early in the illness trajectory, promoting education, and developing policies and procedures that place greater emphasis on comfort and quality of life, particularly for patients with disseminated or advanced-stage disease. 116 In this regard, palliative care may even improve life expectancy for some patients with incurable cancer. 117 Health care providers involved in the care of children with cancer should establish the prognosis, negotiate goals, guide patients and/or their parents in the process of making difficult medical decisions, provide comfort, enhance quality of life, promote care coordination and continuity, optimize comfort at the end of life, and attend to the needs of bereaved family members (Box 1). 118, 119 Despite unanimous recognition and support by national and international organizations for early incorporation of palliative care as a routine part of comprehensive cancer care, further efforts are needed to improve this discipline. There remains significant hetero geneity in the infra structure of this service at cancer centers, and patients continue to be referred to palliative and hospice care late in the disease trajectory in small numbers. 120 
Conclusions
Great strides have been made in the treatment of ALL, NHL and non-CNS germ-cell tumors. Indeed, it is likely that, in the coming decade, 90% of children with these cancers will be disease-free for 5 years, similar to the percentage of survivors with Hodgkin lymphoma and Wilms tumors. By contrast, little or no progress has been made for children with rhabdomyosarcoma, osteosarcoma, Ewing sarcoma, malignant glioma and brain stem glioma over the past two decades, because of intractable drug resistance and because of the limited number of clinical trials being conducted for these tumors. Given that the intensity of chemotherapy has been pushed to the limit of tolerance, and that remarkable progress has been made in understanding cancer cell biology, the prospects of developing effective targeted therapies for these pediatric tumors have never seemed brighter. Perhaps the greatest obstacle to achieving this goal is how to design and implement clinical trials that will identify effective strategies to improve outcomes for progressively smaller subsets of drug-resistant cases that possess specific genetic alterations. With the growing number of potentially useful targeting agents, it will be necessary to cultivate greater international collaboration to test and refine therapies for these cases. It has become increasingly apparent that inter-individual differences in the pharmacodynamics of anticancer drugs that can be caused by both environmental and inherited genetic differences can affect the efficacy and toxicity of treatment. Thus, it is essential to personalize therapy based on host pharmacodynamics and pharmaco genomics to avoid over or under-treatment. Finally, we must be remember that even the most rational and well-tested treatment plans may fail, underscoring the need for comprehensive palliative care to relieve the suffering and improve the quality of life for both patients and their families. 
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